USFDA resolution at Unit III
Unit III received procedural observations from USFDA; while management is confident, any escalation could impact US injectable growth trajectory.
medium · analyst_questionAurobindo Pharma Limited — Q3 FY26
Aurobindo Pharma reported Q3 FY26 consolidated revenue of ₹8,646 crore (+8.4% YoY) and EBITDA of ₹1,773 crore (20.5% margin), driven by strong European growth (+27% YoY to ₹2,70...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
FTC approval for Lannett acquisition
Lannett acquisition requires FTC clearance; any delays or conditions could affect US growth strategy and synergies.
medium · analyst_questionPenicillin-G ramp-up and MIP impact
While MIP on 6-APA/Amoxicillin is positive, the full benefit depends on market price realization and ramp-up execution; predatory pricing risk remains.
low · management_commentaryBiosimilar commercialization timeline
Biosimilar inflection expected only by FY29; near-term revenue contribution remains limited, with ongoing R&D and capex burn.
low · data_observation